UroGen (URGN) Looks Good: Stock Adds 8.1% in Session
UroGen Pharma Ltd. URGN was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $13.68 – $29.11 in the past one-month time frame, witnessed a sharp increase on Friday.
The stock gained after the company declared positive data analysis of its UGN-102 (mitomycin) drug used for treating patients with low-grade intermediate risk non-muscle invasive bladder cancer.
The company has seen no estimate revision in the past month, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
UroGen currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
UroGen Pharma Ltd. Price
A better-ranked stock in the Medical – Biomedical and Genetics industry is Celldex Therapeutics, Inc. CLDX, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Click to get this free report
Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report
UROGEN PHARMA (URGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.